Acthar® Gel (repository corticotropin injection) Reference Bibliography

This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Acthar Gel, as well as publications supported by Mallinckrodt that relate to Acthar directly or indirectly. Human and preclinical studies, health economic and outcomes analyses (HEOR), reports and reviews are included and, where available, links to PubMed are provided.

Updated: August 2019

Nephrology


58. Tumlin JA, Rovin BH, Paxton WG, Ayoub I, Almaani S, Caster DJ, Appel AS, Appel GB. A Prospective, Open Label Study of the safety and treatment efficacy of ACTHar Gel for

60. Tumlin JA, Galphin CM, Rovin BH. Advanced diabetic nephropathy with nephrotic range proteinuria: Long-term efficacy of subcutaneous adrenocorticotropic hormone (ACTH) therapy on proteinuria and urinary vascular endothelial growth factor (VEGF) levels [ASN abstract TH-OR073]. *J Am Soc Nephrol.* 2011;22(suppl):18A


70. Nazareth T, Kariburyo F, Pirani A, Kirkemo A, Xie L, Vaidya N, Philbin M. Patients with Nephrotic Syndrome (NS) receiving Repository Corticotropin Injection (RCI) or Rituximab


**Neurology**


**Neurology – HEOR**


170. Hansen R, Gold L, Schepman P, Niewoeher J, Philbin M. Economic consequences of early versus late use of adrenocorticotropic hormone therapy in infantile spasms [WCI abstract LB10]. Late-breaker abstract presented at World Congress of Inflammation Meeting; August 8-12, 2015; Boston, MA. 2015


Ophthalmology


Ophthalmology HEOR


**Pulmonology**


**Pulmonology – HEOR**


Rheumatology


Gillis TM, Crane M, Hinkle C, Wei N, H.P. Acthar® Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic
therapies with different modes of action [EULAR abstract AB0502]. Ann Rheum Dis. 2015;74(suppl 2):1066-1066


262. Pegram SB. The efficacy and tolerability of H.P. Acthar® Gel (repository corticotropin injection) for the treatment of systemic lupus erythematosus [EULAR abstract AB0531]. Ann Rheum Dis. 2015;74(suppl 2):1077-1078


270. Wu A, June J. Case series: Comparison of repository corticotropin injection (H.P. Acthar Gel) versus glucocorticoids on bone density in SLE patients [ACR abstract 331]. Arthritis Rheumatol. 2017;69(suppl 10): 452

271. Zutshi DW, Friedman M, Ansell BM. Corticotrophin therapy in juvenile chronic polyarthritis (still's disease) and effect on growth. Arch Dis Child. 1971;46(249):584-593. Link
Rheumatology – HEOR


Other


293. Barm TZ. What are the reasons for the strikingly different approaches to the use of ACTH in infants with West Syndrome? *Brain and Development.* 2001;7:647-648. [Link](#)


324. Decker D, Higgins P, Bendele A, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with Etanercept (Enbrel®) [AAI abstract THER5P.902]. J Immunol. 2015;194(suppl 1):139.4-139.4


339. Hogan JJ, Jai R, Gerald BA, Andrew SB, Pietro AC, Maya KR. Treatment of resistant primary focal segmental glomerulosclerosis (FSGS) with adrenocorticotropic hormone (ACTH) gel [ASN abstract SA-PO381]. J Am Soc Nephrol. 2012;23(suppl):725A


341. Jensen MA, Abraham P, Reder AT, Arnason BGW. Co-production of GM-CSF, IL-22, or IL-17F identifies a pathogenic high IL-17A-producing T cell subset from MS patients that is steroid resistant [ANA abstract S151]. Ann Neurology. 2016;80:S53-S54.


345. Kongelbeck SR. Discharge planning for the child with infantile spasms. J Neurosci Nurs. 1990;No. 4:238-244. Link

346. Kontekakis A, Nelson W, Christopher-Stine L, Kelly W, Kobert L, Opong-Owusu B, Reed M. Inclusion body myositis (IBM) symptom flares and associated impact from the patient


374. Lisak RP, Nedelkoska L, Benjamins JA. Melanocortin 4 receptors on oligodendrocytes and oligodendrocyte precursors signal ACTH protection from in vitro death induced by mechanisms involved in cell damage in multiple sclerosis.[ECRIMS abstract P579]. *Mult Scler.* 2015;23(11 suppl 1):273,

375. Lisak R, Nedelkoska L, Benjamins J. ACTH1-39 protection of oligodendrocytes from damage relevant to multiple sclerosis involves both direct and indirect mechanisms. [AAN abstract P2.189]. *Neurology.* 2015;84(suppl 14):P2.189


378. Lisak R, Nedelkoska L, Touil H, Bar-Or A, Benjamins J. Sigma 1 receptor and melanocortin receptor agonists protect oligodendroglia from death induced by products of B cells from multiple sclerosis patients. [ECRIMS abstract P582]. *Mult Scler.* 2018;24(S2):280


383. Mahmoud TG, Frits M, Iannaccone C, Bykerk VP, Bingham C, Weinblatt M, Shadick NA. Correlates of successful flare management: The role of clinician-driven treatment, home-


372. Montroy T, Fiechtner JJ. A single-site, investigator initiated, open-label trial of the adrenocorticotropic hormone (ACTH) analogue HP Acthar Gel (repository corticotropin injection) among subjects with moderately to severely active systemic lupus erythematosus (SLE) [EULAR abstract AB0382]. Ann Rheum Dis. 2013;72(suppl 3):904


375. Obi O, Judson M, Maier L, Wells A, Baughman R. Role of baseline dyspnea index (BDI) and transition dyspnea index (TDI) as a measure of self-reported health related quality of life in sarcoidosis patients [ATS abstract A5609]. Am J Respir Crit Care Med. 2019;199:A5609.


